Juvéderm Ultra XC; Juvéderm Ultra Plus XC
Allergan · Decision date Nov 4, 2026
What did the FDA approve?
This FDA record is a PMA supplement, P050047/S106, for Juvéderm Ultra XC and Juvéderm Ultra Plus XC. The described change is limited to approval for an additional supplier of High Molecular Weight (HMW) Sodium Hyaluronate (NaHA) as a raw material used in manufacture of Juvéderm formulations; the record does not describe a new implant system or a new indication.
The supplied text does not give the supplier name, the prior supplier arrangement, or any updated formulation/specification details beyond that material-source change. It also does not provide independent evidence of safety or clinical effectiveness; it only states the regulatory action on the manufacturing change within the original PMA context.
FDA approval order statement
approval for the use of an additional supplier of High Molecular Weight (HMW) Sodium Hyaluronate (NaHA) as a raw material in the manufacture of Juvéderm formulations.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Nov 4, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P050047/S106
- Regulatory pathway
- PMA supplement
- Applicant
- Allergan
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Nov 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
For the original device and its historical approval scope, see PMA P050047. Subsequent supplements may change the device or its indications.
FDA decision timeline
P050047 · Original PMA
JUVEDERM 24HV, JUVEDERM 30 AND JUVEDERM 30HV GEL IMPLANTS
P050047/S106 received
Application receipt date recorded by FDA.
P050047/S106 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P050047. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050047
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Allergan
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2525 Dupont Dr., Irvine, CA, 92612
Sources and methodology
- Original FDA record: P050047/S106
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



